AUTL logo

AUTL
Autolus Therapeutics Ltd - ADR

3,606
Mkt Cap
$377.92M
Volume
2.15M
52W High
$2.70
52W Low
$1.11
PE Ratio
-1.68
AUTL Fundamentals
Price
$1.42
Prev Close
$1.38
Open
$1.36
50D MA
$1.54
Beta
1.26
Avg. Volume
2.64M
EPS (Annual)
-$0.8652
P/B
1.90
Rev/Employee
$15,648.00
Loading...
Loading...
News
all
press releases
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Moderate Buy" by Brokerages
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has received a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the stock, MarketBeat.com...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
Needham & Company LLC Has Lowered Expectations for Autolus Therapeutics (NASDAQ:AUTL) Stock Price
Needham & Company LLC lowered their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday...
MarketBeat·9d ago
News Placeholder
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell ShuttleTM Platform
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the...
Business Wire·15d ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Shares Up 13.5% on Analyst Upgrade
Autolus Therapeutics (NASDAQ:AUTL) Trading Up 13.5% Following Analyst Upgrade...
MarketBeat·23d ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Given New $11.00 Price Target at Needham & Company LLC
Needham & Company LLC upped their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Monday...
MarketBeat·23d ago
News Placeholder
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 PR Newswire VANCOUVER, BC, Dec. 19...
PR Newswire·1mo ago
News Placeholder
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are covering the company, Marketbeat.com...
MarketBeat·1mo ago
News Placeholder
TFG Asset Management GP Ltd Has $21.66 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL
TFG Asset Management GP Ltd boosted its stake in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 10.5% during the second quarter, according to the company in its most...
MarketBeat·1mo ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Earns Buy Rating from Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Friday...
MarketBeat·1mo ago
News Placeholder
Armistice Capital LLC Increases Stock Position in Autolus Therapeutics PLC Sponsored ADR $AUTL
Armistice Capital LLC raised its holdings in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 9.1% in the second quarter, according to the company in its most recent disclosure...
MarketBeat·1mo ago
<
1
2
...
>

Latest AUTL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.